Table 1

Characteristics of the T1D subjects before treatment

Patient

No.

Age

Gender

Marriage

History

(year)

Height

(cm)

Body

weight

(kg)

C-peptide

(ng/ml)*

Auto-Antibodies

HbA1C

(%)

Insulin dose

(U/day)

IA-2A

GAD

ICA

IAA


Group A: Long-standing patients having some residual islet β cell function and received therapy with CB-SC

1

17

F

No

5

145

35

0.30

-

+

-

-

12.3

52

2

23

F

No

5

167

59

0.56

-

+

-

-

6.6

50

3

38

F

Yes

11

160

60

0.12

-

+

-

-

7.3

23

4

39

F

Yes

1

156

49

0.636

+

+

+

-

11.3

22

5

31

M

Yes

14

170

70

0.18

+

+

-

-

6.5

30

6

30

M

Yes

2

182

70

0.18

-

+

-

-

8.4

40

Mean

(SD)

30

(9)

6

(5)

163

(12.7)

57

(13.4)

0.33

(0.22)

8.7

(2.5)

36.2

(13.2)

Group B: Long-standing severe patients with no residual islet b cell function and received therapy with CB-SC

7

40

M

Yes

17

170

72.5

0.01

-

+

-

-

8.8

48

8

15

F

No

5

163

65

0.01

-

+

-

-

15.5

50

9

21

F

No

4

168

65

0.01

+

-

-

-

9.9

46

10

23

F

No

12

162

80

0.01

+

+

+

-

16.5

60

11

40

F

Yes

21

160

67

0.01

+

-

-

-

8.6

37

12

21

F

No

5

157

56

0.01

-

+

-

-

13.6

50

Mean

(SD)

27

(11)

11

(7)

163

(4.9)

67.6

(8.1)

0.01

(0)

12.2

(3.5)

48.5

(7.4)

Control group: Long-standing patients having some residual islet β cell function and received sham therapy

13

35

M

Yes

1

178

73.5

0.37

+

-

+

-

9.8

30

14

41

M

Yes

14

165

65

0.55

-

+

-

-

6.4

48

15

24

M

No

3

175

58

0.3

-

+

-

-

10.7

48

Mean

(SD)

33

(9)

6

(7)

173

(6.8)

65.5

(7.8)

0.41

(0.13)

9.0

(2.3)

42

(10.4)


*The level of 0.01 ng/ml is the minimum detectable level (sensitivity) of C-peptide by radioimmunoassay (RIA). To convert C-peptide value to nmol/L, multiply the ng/ml by 0.331.

Zhao et al. BMC Medicine 2012 10:3   doi:10.1186/1741-7015-10-3

Open Data